Live Breaking News & Updates on Australian Stock Exchange Ath Ax

Stay updated with breaking news from Australian stock exchange ath ax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alterity Therapeutics to Present New Data on ATH434 at the

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),. ....

United States , San Francisco , Remy Bernarda , Danielo Claassen , Margaret Bradbury , David Stamler , Daniel Claassen , Hannah Howlett , Department Of Pharmaceutical Sciences , Nonclinical Development , European Commission , Alterity Therapeutics , World Orphan Drug Congress United States , American Academy Of Neurology , Wayne State University , National Institute Of Health , Vanderbilt University Medical Center , Parkinson Foundation , Unique Iron Targeting Drug , Treating Friedreich , Pharmaceutical Sciences , Wayne State , American Academy , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy ,

Alterity Therapeutics Receives a A$3.9 Million Research &

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity”. ....

United States , San Francisco , David Stamler , Remy Bernarda , Hannah Howlett , Australian Taxation Office , Development Tax Incentive , Australian Government Research , Alterity Therapeutics , Alterity Therapeutics Limited , European Commission , Therapeutics Limited , Australian Government , Multiple System Atrophy , Multiple System , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Alterity Therapeutics , Clinical Trials , Preclinical Research , Multiple System Atrophy ,

Alterity Therapeutics to Present New Data at the Upcoming

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to. ....

United States , San Francisco , Danielo Claassen , Remy Bernarda , Hannah Howlett , Daniel Claassen , Margaret Bradbury , David Stamler , European Commission , Vanderbilt University , National Institute Of Health , Parkinson Foundation , American Academy Of Neurology , Alterity Therapeutics , International Conference , Vanderbilt University Medical Center , Nonclinical Development , Positive Efficacy Data , Primate Model , Baseline Biomarker Data , American Academy , Chief Executive Officer , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Plight Chain ,

Alterity Therapeutics Phase 2 Data Monitoring Committee

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,. ....

San Francisco , United States , David Stamler , Remy Bernarda , Hannah Howlett , European Commission , Alterity Therapeutics , Drug Administration , Data Monitoring Committee , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Alterity Therapeutics , Multiple System Atrophy , Rare Disease , Clinical Trials ,

Alterity Therapeutics Issues Shareholder Letter

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN. ....

San Francisco , United States , David Stamler , Alterity Therapeutics , Vanderbilt University Medical Center , European Commission , Preliminary Data , Multiple System Atrophy , Orphan Drug Designation , Chief Executive Officer , Multiple System , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Alterity Therapeutics , Multiple System Atrophy ,